Market Size of Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 5.00 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
APAC Bladder Cancer Therapeutics & Diagnostics Market Analysis
Asia-Pacific Bladder Cancer Therapeutics and Diagnostics market is expected to register a CAGR of 5% during the forecast period, owing to increasing burden of bladder cancer and new diagnosis & treatments coming up in the market. According to Globocan, 2018, around 37,293 new cases of bladder cancer were registered in Japan and around 9,943 deaths occurred due to it. This calls for the need of early treatment and diagnosis. Furthermore, new drugs are being developed for the treatment of bladder cancer. In 2020, BeiGene Ltd., recieved an approval from China National Medical Products Administration (NMPA) for anti-PD-1 antibody tislelizumab in the treatment of locally advanced or metastatic urothelial carcinoma (UC). Hence, these factors are expected to drive the growth of the market.
APAC Bladder Cancer Therapeutics & Diagnostics Industry Segmentation
Bladder cancer is a type of tumor that occurs in the cells of the bladder. It grows rapidly and shows uncontrolled growth in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. The Asia-Pacific Bladder Cancer Therapeutics and Diagnostics market is segmented by Product, by Cancer Type, and Geography.
| By Product | ||||||
| ||||||
|
| By Cancer Type | |
| Transitional Cell Bladder Cancer | |
| Squamous Cell Bladder Cancer | |
| Others |
| Geography | ||||||||
|
Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size Summary
The Asia-Pacific bladder cancer therapeutics and diagnostics market is poised for significant growth, driven by the increasing incidence of bladder cancer and advancements in diagnostic and treatment technologies. The market is expected to experience a steady expansion over the forecast period, fueled by the introduction of new drugs and diagnostic devices. The approval of innovative treatments, such as BeiGene Ltd.'s anti-PD-1 antibody tislelizumab in China, highlights the region's commitment to enhancing therapeutic options for bladder cancer. Additionally, the development of advanced diagnostic tools, like bladder ultrasound devices, is anticipated to further propel market growth, as these technologies offer precise early-stage cancer detection.
Key industry players, including AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and others, are actively engaged in expanding their product offerings to capture a larger market share. The competitive landscape is characterized by continuous innovation and regulatory approvals, such as Merck's Keytruda in Japan, which underscores the dynamic nature of the market. As companies strive to enhance their presence and address the growing demand for effective bladder cancer diagnostics and treatments, the market is expected to witness robust development, reflecting the region's proactive approach to tackling this health challenge.
Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Burden of Bladder Cancer
-
1.2.2 Innovation in Drug Development
-
-
1.3 Market Restraints
-
1.3.1 Increased Used of Generic Drugs
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Product
-
2.1.1 By Therapeutics
-
2.1.1.1 Chemotherapy
-
2.1.1.2 Immunotherapy
-
2.1.1.3 Others
-
-
2.1.2 By Diagnostics
-
2.1.2.1 Cystoscopy
-
2.1.2.2 Bladder Ultrasound
-
2.1.2.3 Urinalysis
-
2.1.2.4 Others
-
-
-
2.2 By Cancer Type
-
2.2.1 Transitional Cell Bladder Cancer
-
2.2.2 Squamous Cell Bladder Cancer
-
2.2.3 Others
-
-
2.3 Geography
-
2.3.1 Asia-Pacific
-
2.3.1.1 China
-
2.3.1.2 Japan
-
2.3.1.3 India
-
2.3.1.4 Australia
-
2.3.1.5 South Korea
-
2.3.1.6 Rest of Asia-Pacific
-
-
-
Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size FAQs
What is the current Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market size?
The Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market is projected to register a CAGR of 5% during the forecast period (2024-2029)
Who are the key players in Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market?
F. Hoffmann-La Roche Ltd, Johnson & Johnson, Endo Pharmaceutical Inc., AstraZeneca Plc and Bristol-Myers Squibb Company are the major companies operating in the Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market.
